Erythropoietin, a treatment for newborns with critically low levels of oxygen or blood supply to the brain at birth, does not ...

By Karen Roman ReAlta Life Sciences said it is presenting new data from its hypoxic ischemic encephalopathy (HIE) program at ...

Early onset of severe or moderate neonatal encephalopathy in infants ≥34 wk of gestation *All 3 of the essential criteria are necessary to consider intrapartum hypoxia the etiology of cerebral ...

More information: Natalie H. Chan et al, Neuroprotection for neonatal hypoxic–ischemic encephalopathy: A review of novel therapies evaluated in clinical studies, Developmental Medicine & Child ...

The identification of high-risk patients, often prior to neonatal intensive care unit discharge, allows for early introduction of services, an important intervention to promote optimal outcomes ...

Neonatal hypoxic-ischemic encephalopathy (HIE) is the most frequent neurologic disease in the perinatal period. Its major cause is oxidative stress, which induces DNA peroxidation and apoptotic ...

To establish if miRNA could serve as diagnostic biomarkers, Kobeissy and his team acquired blood samples from infants who experienced hypoxic stress in utero from the Florida Neonatal Neurologic ...

The Company’s lead candidate, RLS-0071 (pegtarazimod), has received FDA Orphan Drug Designation and Fast Track Designations for hypoxic ischemic encephalopathy (HIE), a devastating disease that ...